Effect of a Novel Agent SL-401, Targeting Interleukin-3 Receptor (IL-3R) on Plasmacytoid Dendritic Cell (pDC)-Induced Myeloma Cell Growth and Osteolytic Bone Disease
Effect Of A Novel Agent SL-401, Targeting Interleukin-3 Receptor (IL-3R) On Plasmacytoid Dendritic Cell (pDC)-Induced Myeloma Cell Growth And Osteolytic Bone Disease. ASCO 2014.
